Literature DB >> 16720944

Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins.

Christian Schmeer1, Alexandra Kretz, Stefan Isenmann.   

Abstract

PURPOSE: The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or "statins", are used as cholesterol-lowering agents worldwide. This review, focused on recent experimental and clinical data, summarizes general mechanisms of statin actions underlying neuroprotective effects in the central nervous system (CNS) and presents evidence for putative mechanisms involving heat shock proteins and the survival-related PI-3K/Akt pathway that may be beneficial for the treatment of neurological disorders.
METHODS: We carried out a medline search on statin actions, with respect to biochemical pathways and signal transduction on the one hand, and clinical studies in neurologic and retinal diseases on the other hand. Novel experimental data obtained in a rat model of axonal CNS injury were also included.
RESULTS: Statins exert multiple effects on endothelial function, cell proliferation, inflammatory response, immunological reactions, platelet function, and lipid oxidation. These "pleiotropic actions" are independent of cholesterol lowering and appear to be beneficial in the context of brain injury. Several mechanisms of statin actions underlying neuroprotective effects may also involve heat shock proteins and the survival-related PI-3K/Akt pathway.
CONCLUSIONS: Available data suggest that statins may be of potential therapeutic use in a variety of diseases of the CNS including ischemic stroke, Alzheimer's disease, multiple sclerosis and some forms of retinal and eye diseases. Before general recommendations can be made and specific therapeutic approaches can be developed, more reliable clinical data and studies are required, and possible side effects must be carefully evaluated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720944

Source DB:  PubMed          Journal:  Restor Neurol Neurosci        ISSN: 0922-6028            Impact factor:   2.406


  16 in total

1.  The relationship between statin use and open-angle glaucoma.

Authors:  Joshua D Stein; Paula Anne Newman-Casey; Nidhi Talwar; Bin Nan; Julia E Richards; David C Musch
Journal:  Ophthalmology       Date:  2012-06-21       Impact factor: 12.079

2.  The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system.

Authors:  Scott L Letendre; Jennifer Marquie-Beck; Ronald J Ellis; Steven Paul Woods; Brookie Best; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Terry J Alexander; Janis Durelle; Robert Heaton; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-03       Impact factor: 4.147

Review 3.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

4.  Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.

Authors:  Raffaele Palladino; Ruth Ann Marrie; Azeem Majeed; Jeremy Chataway
Journal:  JAMA Neurol       Date:  2020-07-01       Impact factor: 18.302

Review 5.  Eye on statins: A comprehensive review.

Authors:  Evan A Olson; Dean P Hainsworth; Geetha Davis; John C Hagan
Journal:  Mo Med       Date:  2013 Jul-Aug

6.  Association of Statin Use and High Serum Cholesterol Levels With Risk of Primary Open-Angle Glaucoma.

Authors:  Jae H Kang; Tahani Boumenna; Joshua D Stein; Anthony Khawaja; Bernard A Rosner; Janey L Wiggs; Louis R Pasquale
Journal:  JAMA Ophthalmol       Date:  2019-07-01       Impact factor: 7.389

7.  Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model.

Authors:  Metin Unlu; Zeynep Aktas; Pinar Uyar Gocun; Sevil Ozger Ilhan; Murat Hasanreisoglu; Berati Hasanreisoglu
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

Review 8.  Promoting successful cognitive aging: a comprehensive review.

Authors:  Kirk R Daffner
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

9.  Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration.

Authors:  Ilse S Pienaar; Timothy Schallert; Suzél Hattingh; William M U Daniels
Journal:  J Neural Transm (Vienna)       Date:  2009-06-06       Impact factor: 3.575

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.